



ACADEMIA NACIONAL DE MEDICINA DE MÉXICO

Distinguidos Académicos:

La Mesa Directiva de la Academia Nacional de Medicina, les enviamos el siguiente comunicado que el Gerente de *Elsevier Journals*, *Philippe Terheggen*, nos ha hecho llegar.

ELSEVIER

Editor Briefings

Update on our Covid-19 related initiatives

Dear Dr. Corona-Vázquez,

The current COVID-19 pandemic affects us all and I very much hope that you, your families and colleagues are safe and well.

Before anything else, I'd like to express my sincere appreciation for the efforts of all of you who are on the front lines, fighting the pandemic, trying to understand the biology of COVID-19, developing tools and treatments, or caring for people affected by the virus. In this situation, our unity – though we cannot express this face-to-face – is what will help move us through the pandemic, and I thank each and every one of you for all you are doing.

Our priority is to do everything we can to ensure the continued safety and wellbeing of our employees, customers and partners. At this time, we are not seeing any major impact to our journal services. In these unprecedented times, we consider it more important than ever that we continue to publish relevant and timely research results. Obviously, you as editors and editorial board members play an instrumental role in this process.

We are therefore doing our utmost to support you, and the research community, for example:

- We have created an [editor resilience center](#), a new support hub to you to continue your regular editorial activities. We have created a similar [resilience center for our authors](#).
- In order to ensure access for all our readers, we have [an extensive guide](#) including webcasts on how to get remote access to our platforms like ScienceDirect, Scopus and Reaxys. All our ScienceDirect article pages now also include a link to our [remote access options](#).
- Earlier this year, we established the [Novel Coronavirus Information Center](#) with the latest



ACADEMIA NACIONAL DE MEDICINA DE MÉXICO

research and information, including [a link](#) to almost 20,000 textbook chapters and articles from across all our journals including *Cell* and *The Lancet*. All are freely available freely to help the global response.

- We have made all our Covid-19 related research and data content available to PubMed Central, and also made it freely available for download from the [Information Center](#) in a machine-readable format with rights for full text and data mining, re-use and analyses, for as long as needed.

As the COVID-19 pandemic is expanding rapidly, the needs from authors and reviewers may vary across the globe, making a “one size fits all” approach less suitable. I encourage you to be flexible towards requests from authors and reviewers (for example, with regards to extending deadlines) and discuss any specific requests you may receive with your Publishing contact.

Lastly, I understand that many of you may be experiencing a significant disruption of your regular editorial activities. If you are faced with any challenges, I urge you to reach out to your Publishing contact to discuss what we might be able to do to help. We will do all we can to support you.

I am very grateful for your ongoing support to the journal, even in these times where you may well have concerns for others and for yourself.

My sincere thanks to you,
Philippe Terheggen
Managing Director, Elsevier Journals

This message has been sent to coronav@unam.mx from Elsevier Communications on behalf of Elsevier Journals.

If you no longer wish to receive messages of this nature from us in the future, please [click here](#).

Visit the [Preference Center](#) to manage more of your communication preferences with us.

Copyright © 2020 [Elsevier B.V.](#). All rights reserved. | [Elsevier Privacy Policy](#)

Elsevier B.V. Registered Office: Radarweg 29, 1043 NX Amsterdam, The Netherlands. Reg. No. 33158992 – Netherlands. VAT No. NL 005033019B01.

ELSEVIER